LIVIVO - Search results -

Search results

Result 1 - 10 of total 126

Search options

Article: Un accompagnement multidisciplinaire indispensable pour la prise en charge de la sclérose en plaques.

Maillart, Élisabeth

2023 Volume 68, Issue 873, Page(s) 14–18

Abstract: Multiple sclerosis (MS) is a chronic inflammatory pathology of the central nervous system, which affects young subjects. MS requires a multidisciplinary care coordinated between specialists and allied health professionals. A close collaboration is needed ...

Title translation	Multidisciplinary support is essential for the management of multiple sclerosis.
Abstract	Multiple sclerosis (MS) is a chronic inflammatory pathology of the central nervous system, which affects young subjects. MS requires a multidisciplinary care coordinated between specialists and allied health professionals. A close collaboration is needed between the various praticians. The last decades have been marked by very significant progress, the diagnosis being established earlier and disease-modifying treatments introduced earlier, with the use of high-efficiency treatments. These therapeutic advances are exciting, however efforts are still needed to better understand the mechanisms of myelin repair and neurodegeneration.
MeSH term(s)	Humans ; Multiple Sclerosis/diagnosis ; Multiple Sclerosis/drug therapy ; Inflammation
Language	French
Publishing date	2023-03-23
Publishing country	France
Document type	English Abstract ; Journal Article
ZDB-ID	604655-1
ISSN	0038-0814
ISSN	0038-0814
DOI	10.1016/j.soin.2023.02.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2545: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical characteristics of patients with myelin oligodendrocyte glycoprotein antibodies.

Maillart, Elisabeth / Deiva, Kumaran / Marignier, Romain

Current opinion in neurology

2024 Volume 37, Issue 3, Page(s) 338–344

Abstract: Purpose of review: The clinical landscape associated to myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) has undergone a remarkable transformation over the past two decades, primarily driven by advancements in antibody detection techniques that ... ...

Abstract	Purpose of review: The clinical landscape associated to myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) has undergone a remarkable transformation over the past two decades, primarily driven by advancements in antibody detection techniques that have enhanced both the specificity and sensitivity of assays, enabling the identification of novel clinical phenotypes. Recent findings: Recent pivotal research publications, comprehensive reviews from established research groups, and most notably the first proposed international criteria for MOG-Ab associated disease (MOGAD) have substantially enriched our understanding of the clinical features associated with MOG-Ab. This review presents a comprehensive overview of the clinical characteristics of patients with MOG-Ab, systematically examining each core clinical syndrome defined by the proposed international MOGAD criteria. We incorporated recent insights and discussed potential challenges in applying these criteria across diverse clinical scenarios. Summary: The proposed international MOGAD criteria provide a comprehensive, homogeneous, and specific framework for characterizing the clinical features of patients with MOG-Ab, encompassing both paediatric and adult populations. In the future, the widespread adoption of specific and reliable assays for MOG-Ab detection, complemented by the development of surrogate fluid and imaging markers, holds promise for better characterizing atypical presentations, only-cerebrospinal fluid positivity and the MOGAD "seronegative" situations.
MeSH term(s)	Humans ; Myelin-Oligodendrocyte Glycoprotein/immunology ; Autoantibodies/immunology
Chemical Substances	Myelin-Oligodendrocyte Glycoprotein ; Autoantibodies ; MOG protein, human
Language	English
Publishing date	2024-03-18
Publishing country	England
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	1182686-1
ISSN	1473-6551 ; 1350-7540
ISSN (online)	1473-6551
ISSN	1350-7540
DOI	10.1097/WCO.0000000000001265
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2524: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Grossesse et sclérose en plaques.

Maillart, Élisabeth / Papeix, Caroline

La Revue du praticien

2022 Volume 72, Issue 4, Page(s) 394–398

Abstract: Pregnancy and multiple sclerosis Pregnancy is a possibility for a patient with multiple sclerosis, but it is best to anticipate and plan for it. Pregnancy does not worsen the disability in the long term. The risk of relapse in the 3 months postpartum ... ...

Title translation	Multiple sclerosis and pregnancy.
Abstract	"Pregnancy and multiple sclerosis Pregnancy is a possibility for a patient with multiple sclerosis, but it is best to anticipate and plan for it. Pregnancy does not worsen the disability in the long term. The risk of relapse in the 3 months postpartum depends on the risk of relapse in the year preceding the pregnancy; it is therefore preferable to plan a pregnancy when the multiple sclerosis is stabilized. The maintenance of background treatment in preconception or during pregnancy depends on the type of medication, the risk for the child (miscarriage, malformations) but also the risk of rebound in the mother. Pregnancy fol-low-up and mode of delivery are comparable to those of the general population. Epidural analgesia is not contraindicated. The decision to breastfeed must take into account the patient's wishes and the severity of the disease (contraindication of breastfeeding with certain background treatments). There is no validated preventive treatment for postpartum relapses."
MeSH term(s)	Breast Feeding ; Child ; Female ; Humans ; Multiple Sclerosis/diagnosis ; Multiple Sclerosis/epidemiology ; Multiple Sclerosis/therapy ; Postpartum Period ; Pregnancy ; Pregnancy Complications/diagnosis ; Pregnancy Complications/therapy ; Recurrence
Language	French
Publishing date	2022-05-31
Publishing country	France
Document type	Journal Article
ZDB-ID	205365-2
ISSN	2101-017X ; 0035-2640
ISSN (online)	2101-017X
ISSN	0035-2640
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.433: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Neuromyélite optique.

Roux, Thomas / Maillart, Élisabeth / Papeix, Caroline

La Revue du praticien

2023 Volume 73, Issue 1, Page(s) 79–83

Abstract: NEUROMYELITIS OPTICA. Neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) includes different inflammatory conditions of the central nervous system distinct from multiple sclerosis. It is characterized by the association of ... ...

Title translation	Neuromyelitis optica.
Abstract	NEUROMYELITIS OPTICA. Neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) includes different inflammatory conditions of the central nervous system distinct from multiple sclerosis. It is characterized by the association of typical clinical manifestations, such as optic neuritis, extensive transverse myelitis, involvement of the area postrema, and by the presence of anti-aquaporin 4 antibodies. It evolves with relapses. These can be lethal and justify emergency treatment with the administration of high dose of intravenous corticosteroids possibly associated with plasma exchange sessions. A disease modifying treatment is then started to prevent the occurrence of a new relapse.
MeSH term(s)	Humans ; Neuromyelitis Optica ; Autoantibodies/therapeutic use ; Multiple Sclerosis/complications
Chemical Substances	Autoantibodies
Language	French
Publishing date	2023-02-11
Publishing country	France
Document type	English Abstract ; Journal Article
ZDB-ID	205365-2
ISSN	2101-017X ; 0035-2640
ISSN (online)	2101-017X
ISSN	0035-2640
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.433: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.

Sahloul, Oussama / Louapre, Céline / Beigneux, Ysoline / Lubetzki, Catherine / Maillart, Elisabeth / Roux, Thomas

Multiple sclerosis and related disorders

2024 Volume 85, Page(s) 105557

Abstract: Background: Multiple sclerosis (MS) predominantly affects women of childbearing age. Due to the risk of teratogenicity, women with active multiple sclerosis (MS) who require high-efficacy therapies (HET) may need to discontinue treatment during ... ...

Abstract	Background: Multiple sclerosis (MS) predominantly affects women of childbearing age. Due to the risk of teratogenicity, women with active multiple sclerosis (MS) who require high-efficacy therapies (HET) may need to discontinue treatment during pregnancy. Fingolimod and Natalizumab withdrawal increases the risk of disease reactivation, a risk not commonly associated with anti-CD20 therapies. However, comparative data are limited during pregnancy and post-partum. Our aim was to compare evidence of disease activity during pregnancy and post-partum in women treated with HET (anti-CD20 therapies, Natalizumab or Fingolimod) before conception, whether or not exposed during pregnancy. Methods: In this single-center retrospective study, we included consecutive pregnancies of relapsing-remitting MS patients and classified them in three groups according to the last HET used before conception: « anti-CD20 » « Natalizumab (NTZ) » and « Fingolimod (FGD) ». The main outcome was annualized relapse rate (ARR) during pregnancy and post-partum. Results: We included 66 pregnancies: 21, 24 and 21 in anti-CD20, NTZ and FGD groups respectively. Overall, mean ARR (SD) increased from 0.36 (0.6) during the preconception year to 0.60 (1.3) during pregnancy and to 1.03 (2.0) in the first 3 months post-partum. Mean ARR in anti-CD20 group (0.09 (0.3)) during pregnancy and the first 3 months post-partum was lower compared with NTZ (0.48 (0.6); p = 0,09) and FGD (1.50 (1.8); p = 0.001) groups. Proportion of pregnancies with radiological activity during pregnancy and post-partum in anti-CD20 group (5.2 %) was lower compared with NTZ (63.1 %; p < 0.001) and FGD (72.2 %; p < 0.001) groups. There was no significant difference in the evolution of EDSS score from conception to post-partum between each group (p = 0.75). Conclusion: Evidence of disease activity was significantly lower in patients exposed to anti-CD20 therapies before conception. This study suggests that use of anti-CD20 therapies is an efficient option to prevent disease reactivation during pregnancy and post-partum.
MeSH term(s)	Humans ; Female ; Pregnancy ; Adult ; Natalizumab/adverse effects ; Retrospective Studies ; Postpartum Period ; Pregnancy Complications/drug therapy ; Fingolimod Hydrochloride/adverse effects ; Fingolimod Hydrochloride/therapeutic use ; Immunologic Factors/adverse effects ; Immunologic Factors/administration & dosage ; Immunologic Factors/pharmacology ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Immunosuppressive Agents/adverse effects
Chemical Substances	Natalizumab ; Fingolimod Hydrochloride (G926EC510T) ; Immunologic Factors ; Immunosuppressive Agents
Language	English
Publishing date	2024-03-19
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2645330-7
ISSN	2211-0356 ; 2211-0348
ISSN (online)	2211-0356
ISSN	2211-0348
DOI	10.1016/j.msard.2024.105557
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Multiple sclerosis in 2020: un bon cru.

Maillart, Elisabeth / Lubetzki, Catherine

The Lancet. Neurology

2020 Volume 20, Issue 1, Page(s) 12–13

MeSH term(s)	Animals ; COVID-19/epidemiology ; Clinical Trials as Topic ; Humans ; Multiple Sclerosis/diagnostic imaging ; Multiple Sclerosis/drug therapy ; Multiple Sclerosis/metabolism ; Multiple Sclerosis/therapy ; Neuroprotective Agents/pharmacology
Chemical Substances	Neuroprotective Agents
Language	English
Publishing date	2020-12-10
Publishing country	England
Document type	Journal Article
ZDB-ID	2081241-3
ISSN	1474-4465 ; 1474-4422
ISSN (online)	1474-4465
ISSN	1474-4422
DOI	10.1016/S1474-4422(20)30441-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5955: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Risk factors and prognosis of orotracheal intubation in aquaporin-4-IgG neuromyelitis optica spectrum disorder attacks.

Januel, Edouard / Brochard, Vincent / Le Guennec, Loïc / Maillart, Elisabeth / Louapre, Céline / Lubetzki, Catherine / Weiss, Nicolas / Demeret, Sophie / Papeix, Caroline

Annals of intensive care

2024 Volume 14, Issue 1, Page(s) 4

Abstract: Background: Aquaporin-4 immunoglobulin G Neuro Myelitis Optica spectrum disorders attacks (NMOSD-AQP4-IgG+ attacks) can cause respiratory failure requiring orotracheal intubation (OTI), but the risk factors and outcomes of OTI during attacks remain ... ...

Abstract	Background: Aquaporin-4 immunoglobulin G Neuro Myelitis Optica spectrum disorders attacks (NMOSD-AQP4-IgG+ attacks) can cause respiratory failure requiring orotracheal intubation (OTI), but the risk factors and outcomes of OTI during attacks remain unclear. Our primary objective was to identify the clinical and radiological risk factors for OTI in NMOSD-AQP4-IgG+ attacks. As a secondary objective, we aimed to evaluate the prognosis of OTI-attacks. Methods: We retrospectively analyzed NMOSD-AQP4-IgG+ attacks at the Pitié-Salpêtrière Hospital (Jan 2010-Jan 2021), excluding isolated optic neuritis. The primary outcome was the need for OTI due to neurological dysfunction an attack (OTI-attack). The secondary outcome was attack's poor recovery after 12 months, defined as a modified Rankin score (mRS) > 2 in patients with an initial mRS ≤ 2, or an increase ≥ 1 point in mRS in other patients. Analyses were performed using a binomial generalized linear mixed model, with a random intercept for the patient ID to account for within-patient correlations. Results: Seventy-three attacks in 44 patients NMOSD-AQP4-IgG+ were analyzed. Of 73 attacks, 8 (11%) required OTI during the attack, related to acute restrictive respiratory failure (n = 7) and/or severe swallowing disorder (n = 2). None of the OTI-attacks occurred in patients previously treated with active disease-modifying treatment (DMT), while 36 (55.4%) of the non-OTI-attacks occurred in patients who were already on active DMT. On admission, OTI-attacks were more likely to have upper limbs motor paresis of (75.0% versus 29.2%, p = 0.366) and dyspnea (3 [50.0%] versus 4 [6.6%], p = 0.002) compared to non-OTI-attacks. MRI analysis showed that OTI-attacks had edematous lesions in the cervical spinal cord, mainly at levels C1 (75% versus 0% in non-OTI-attacks), C2 (75% versus 1.9%), C3 (62.5% versus 1.9%), and C4 and C5 levels (50% versus to 3.9%). One OTI-attack resulted in the death of one patient. Five patients with OTI-attack had mRS ≤ 2 one year after OTI-attack. Two (25%) OTI-attacks had poor recovery compared to 15 (24.2%) non-OTI-attacks (p = 0.468). Conclusion: OTI-attacks occurred in untreated NMOSD-AQP4-IgG+ patients and were associated with edematous upper cervical lesions. The prognosis of these attacks may be favorable, and warrant maximal medical and supportive treatment. Trial registration This was a retrospective observational monocentric cohort study nested in the NOMADMUS cohort (ClinicalTrials.gov Identifier: NCT02850705).
Language	English
Publishing date	2024-01-08
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2617094-2
ISSN	2110-5820
ISSN	2110-5820
DOI	10.1186/s13613-023-01213-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Treatments of paediatric multiple sclerosis: Efficacy and tolerance in a longitudinal follow-up study.

Saponaro, Anne-Charlotte / Tully, Thomas / Maillart, Elisabeth / Maurey, Hélène / Deiva, Kumaran

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society

2023 Volume 45, Page(s) 22–28

Abstract: Aim: To compare the efficacy and safety of newer and/or second-line disease-modifying treatments (DMTs) with interferon beta-1a.: Method: This observational retrospective study included patients younger than 18 years old in the French KIDBIOSEP ... ...

Abstract	Aim: To compare the efficacy and safety of newer and/or second-line disease-modifying treatments (DMTs) with interferon beta-1a. Method: This observational retrospective study included patients younger than 18 years old in the French KIDBIOSEP cohort who had a diagnosis of relapsing multiple sclerosis between 2008 and 2019 and received at least one DMT. Primary outcome was the annualized relapse rate (ARR). Secondary outcomes were the risk of new T2 or gadolinium-enhanced lesions on brain MRI. Results: Among 78 patients enrolled, 50 were exposed to interferon and 76 to newer DMTs. Mean ARR went from 1.65 during pre-treatment period to 0.45 with interferon (p < 0.001). Newer DMTs reduced ARR compared to interferon: fingolimod 0.27 (p = 0.013), teriflunomide 0.25 (p = 0.225), dimethyl-fumarate 0.14 (p = 0.045), natalizumab 0.03 (p = 0.007). Risk of new lesions on MRI was reduced with interferon compared to pre-treatment period; it decreased even more with newer DMTs for T2 lesions. Regarding risk of new gadolinium-enhanced lesions, the added value of new treatments compared to interferon was less obvious, except for natalizumab (p = 0.031). Conclusion: In this real-world setting, newer DMTs showed better efficacy than interferon beta-1a on ARR and risk of new T2 lesions, with a good safety profile. Natalizumab tend to emerge as the most effective treatment.
MeSH term(s)	Child ; Humans ; Adolescent ; Multiple Sclerosis ; Follow-Up Studies ; Interferon beta-1a ; Natalizumab ; Retrospective Studies ; Gadolinium ; Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Immunosuppressive Agents
Chemical Substances	Interferon beta-1a (XRO4566Q4R) ; Natalizumab ; Gadolinium (AU0V1LM3JT) ; Immunosuppressive Agents
Language	English
Publishing date	2023-05-11
Publishing country	England
Document type	Observational Study ; Journal Article
ZDB-ID	1397146-3
ISSN	1532-2130 ; 1090-3798
ISSN (online)	1532-2130
ISSN	1090-3798
DOI	10.1016/j.ejpn.2023.05.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4867: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 641: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Longitudinally extensive posterolateral myelitis revealing invasive CNS aspergillosis in an immunocompetent patient.

Jeantin, Lina / Leclercq, Delphine / Tran, Suzanne / Maillart, Elisabeth / Reina, Vincent / Fekkar, Arnaud / Lanternier, Fanny / Marois, Clémence / Celier, Adam

Multiple sclerosis (Houndmills, Basingstoke, England)

2024 Volume 30, Issue 6, Page(s) 755–758

Abstract: Background: Fungal infections of the central nervous system usually affect immunocompromised patients. Primary : Report: A 45-year-old immunocompetent male with subacute paraplegia was treated for inflammatory myelitis before clinical deterioration ... ...

Abstract	Background: Fungal infections of the central nervous system usually affect immunocompromised patients. Primary Report: A 45-year-old immunocompetent male with subacute paraplegia was treated for inflammatory myelitis before clinical deterioration requiring mechanical ventilation. Purulent meningitis preceded the formation of a paraspinal nodule biopsied by neurosurgery. Histopathological analysis revealed the presence of fungal hyphae, and polymerase chain reaction was positive for Discussion: Primary
MeSH term(s)	Humans ; Male ; Middle Aged ; Myelitis/microbiology ; Aspergillus fumigatus/isolation & purification ; Immunocompetence ; Magnetic Resonance Imaging ; Neuroaspergillosis ; Aspergillosis/complications ; Aspergillosis/diagnosis ; Antifungal Agents/therapeutic use
Chemical Substances	Antifungal Agents
Language	English
Publishing date	2024-01-21
Publishing country	England
Document type	Case Reports ; Journal Article
ZDB-ID	1290669-4
ISSN	1477-0970 ; 1352-4585
ISSN (online)	1477-0970
ISSN	1352-4585
DOI	10.1177/13524585231221680
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4428: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Accompagnement du patient attaint de sclérose en plaques

Maillart, Élisabeth / Papeix, Caroline

La Revue du praticien

2018 Volume 66, Issue 1, Page(s) 37–40

Abstract: Multiple sclerosis patient's support. Multiple sclerosis (MS) is an inflammatory chronic pathology of the central nervous system, and the second cause of acquired disability for young adults. It requires a multidisciplinary care coordinated between ... ...

Title translation	Multisclerosis patient's support
Abstract	Multiple sclerosis patient's support. Multiple sclerosis (MS) is an inflammatory chronic pathology of the central nervous system, and the second cause of acquired disability for young adults. It requires a multidisciplinary care coordinated between specialists and allied health professionals. A close collaboration is needed between the various patricians, especially between the neurologist and the general practitioner. The general practitioner plays a key role in the management of MS patients during the various stages: first signs to evaluated steps, including announcement diagnosis.
MeSH term(s)	Humans ; Multiple Sclerosis/rehabilitation ; Patient Care Team ; Specialization ; Young Adult
Language	French
Publishing date	2018-12-03
Publishing country	France
Document type	Journal Article
ZDB-ID	205365-2
ISSN	2101-017X ; 0035-2640
ISSN (online)	2101-017X
ISSN	0035-2640
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.433: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito